A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer

Inclusion Criteria:

1. Fully understand the study and sign the informed consent form voluntarily;
2. Patients with local advanced and/or metastatic gastric cancer confirmed by histology and/or cytology;
3. Fail in previous first-line standard chemotherapy
4. Aged 18-70years (inclusive);
5. Body weight ≥40 kg;
6. At least one measurable lesion (according to RECIST1.1);
7. Physical status score (ECOG score) 0-1;
8. Expected survival \>12 weeks.

Exclusion Criteria:

1. Who are participating in another drug clinical trial in the past 4 weeks; or receive systemic anti-tumor chemotherapy, radiotherapy or biotherapy within 4 weeks prior to administration of the study drug;
2. Who previously received VEGF/VEGFR inhibitors;
3. Who have not recovered from toxicity caused by previous anti-cancer treatment (CTCAE\>grade 1), or not completely recovered from previous surgery;
4. Active brain metastasis(with clinical symptom);
5. Other malignancies except squamous-cell or basal cell carcinoma, and cervical carcinoma in situ in the past 5 years;
6. Uncontrolled clinical active infection, e.g. acute pneumonia, hepatitis B or active hepatitis C;
7. Dysphagia, intractable vomiting or known drug malabsorption;